Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 13/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.42 |
| ▸ | CDK4 | P11802 | 7/20 | 0.42 |
| ▸ | CCND1 | P24385 | 7/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13230437 | 0.88 | JAK2 (0.42) | CDK2CCNE2CCNE1CDK4CCND1 | |
| SCHEMBL13230440 | 0.85 | JAK2 (0.40) | CDK2CCNE2CCNE1CDK4CCND1 | |
| SCHEMBL15267989 | 0.84 | MAT2A (0.42) | RAB9ATRPV1EGFR | |
| SCHEMBL5262734 | 0.81 | ALDH1A1 (0.43) | LMNARAB9ATRPV1EGFR | |
| SCHEMBL13262214 | 0.81 | PTPN1 (0.40) | LMNACD38TRPV1EGFR | |
| SCHEMBL13230436 | 0.80 | JAK2 (0.43) | CDK2CCNE2CCNE1CDK4CCND1 | |
| SCHEMBL13230425 | 0.77 | RAB9A (0.42) | CDK2CCNE2CCNE1CDK4CCND1 | |
| SCHEMBL13853282 | 0.76 | ALDH1A1 (0.39) | LMNARAB9ASMN1; SMN2 | |
| SCHEMBL13230448 | 0.74 | JAK2 (0.39) | JAK2JAK1NPC1LMNATP53 | |
| SCHEMBL15268025 | 0.73 | PDPK1 (0.41) | LMNATP53HPGDTRPV1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546405-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2013-10-01 | — | — | US | disclosed |
| US-8541424-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2013-09-24 | — | — | US | disclosed |
| US-20100168138-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100160355-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168138-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CDK2 113/4885CCNE2 438/4885CCNE1 932/4885 |
| US-20100160355-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CDK2 113/4885CCNE2 438/4885CCNE1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.